



Clinical trial results:

A phase IV, open-label single-arm study investigating the pharmacokinetics and pharmacodynamics of the antiretroviral combination of rilpivirine and ritonavir-boosted darunavir in therapy-naïve HIV-1 infected patients.

Summary

EudraCT number	2012-002663-10
Trial protocol	GB
Global end of trial date	16 March 2015

Results information

Result version number	v1 (current)
This version publication date	14 September 2017
First version publication date	14 September 2017

Trial information

Trial identification

Sponsor protocol code	SSAT049
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01736761
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	St Stephens Aids Trust
Sponsor organisation address	Chelsea Chambers, 262a Fulham Road, LONDON, United Kingdom, SW10 9EL
Public contact	Marita Marshall, Head of Project Management, St Stephen's Clinical Research, +44 203 828 0567, marita.marshall@ststcr.com
Scientific contact	Marta Boffito, Chief Investigator, St Stephan's Centre, Chelsea & Westminster Hospital, +44 208 846 6507, marta.boffito@nhs.net

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 January 2017
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	16 March 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To describe the rate of virologic suppression after 48 weeks of therapy with the study regime

Protection of trial subjects:

The protocol was written, and the study was conducted according to the ICH Harmonized Tripartite Guideline on Good Clinical Practice, E6 and the principles of the Declaration of Helsinki. The protocol was approved by the National Regulator and an Independent Ethics Committee as required by national legislation.

Written informed consent was obtained from each subject prior to evaluations being performed for eligibility. Subjects were given adequate time to review the information in the informed consent and were encouraged to ask questions concerning all portions of the conduct of the study to ensure understanding. The purpose of the study together with the procedures benefits and risks of the study; any discomforts and the precautions taken was described during the consent process; allowing subject to make an informed decision about participation. Subjects were also informed of their right to discontinue from the study at any time without any detriment.

The inclusion/exclusion criteria were designed to eliminate subjects who may have been put at risk by participating in the study. Women of child-bearing potential and heterosexual males, were required to use an effective barrier contraceptive method or remain sexually abstinent for the duration of the study. Subjects were required to refrain from strenuous exercise, contact sports and sunbathing for the first 12 weeks of the study. Activities known to impact drug metabolism [Exercise, smoking, and consumption of alcohol/grapefruit/St John's Wort/Caffeine] were restricted or prohibited during the study period. Safety and tolerability of medications were assessed by questions, physical examination and laboratory parameters. Any changes in health status during the study were recorded and followed up by the clinical team.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 November 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 36
Worldwide total number of subjects	36
EEA total number of subjects	36

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	36
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects were stratified based on pre-treatment viral load; <100,000 copies/mL (LOW- Group A) ≥ 100,000 copies/mL (HIGH Group B). After 10 participants were recruited to group A, a protocol steering committee reviewed viral load responses after first four weeks of therapy prior to recruitment of participants to group B.

Pre-assignment

Screening details:

37 subjects were screened for the study and 36 were enrolled

Pre-assignment period milestones

Number of subjects started	36
Number of subjects completed	36

Period 1

Period 1 title	Whole Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Low Copy

Arm description:

pre-treatment viral load <100,000 copies/mL

Arm type	Experimental
Investigational medicinal product name	Norvir
Investigational medicinal product code	J05AE03
Other name	ritonavir.
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg once a day

Investigational medicinal product name	PREZISTA
Investigational medicinal product code	J05AE10
Other name	Darunavir
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

800 mg once daily

Investigational medicinal product name	EDURANT
Investigational medicinal product code	J05AG05
Other name	Rilpivirine
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

25 mg once daily - Rilpivirine must be taken with a meal of at least 533kcal

Arm title	High
------------------	------

Arm description:

pre-treatment viral load equal to or above 100,000 copies/mL

Arm type	Experimental
Investigational medicinal product name	Norvir
Investigational medicinal product code	J05AE03
Other name	ritonavir.
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg once a day

Investigational medicinal product name	PREZISTA
Investigational medicinal product code	J05AE10
Other name	Darunavir
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

800 mg once daily

Investigational medicinal product name	EDURANT
Investigational medicinal product code	J05AG05
Other name	Rilpivirine
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

25 mg once daily - Rilpivirine must be taken with a meal of at least 533kcal

Number of subjects in period 1	Low Copy	High
Started	18	18
Completed	18	18

Baseline characteristics

Reporting groups

Reporting group title	Whole Study
-----------------------	-------------

Reporting group description: -

Reporting group values	Whole Study	Total	
Number of subjects	36	36	
Age categorical			
Age Categories			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	36	36	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	32.3		
standard deviation	± 8.4	-	
Gender categorical			
Units: Subjects			
Female	1	1	
Male	35	35	

End points

End points reporting groups

Reporting group title	Low Copy
Reporting group description: pre-treatment viral load <100,000 copies/mL	
Reporting group title	High
Reporting group description: pre-treatment viral load equal to or above 100,000 copies/mL	
Subject analysis set title	Combined Analysis
Subject analysis set type	Full analysis
Subject analysis set description: Combined high and low arms	

Primary: The decline in HIV-1 RNA level (log10 copies/ml) from baseline to wk 1

End point title	The decline in HIV-1 RNA level (log10 copies/ml) from baseline to wk 1 ^[1]
End point description: The decline in HIV-1 RNA level (log10 copies/ml)	
End point type	Primary
End point timeframe: Baseline to week 1	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: descriptive statistics only

End point values	Low Copy	High		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	18		
Units: copies/ml				
median (inter-quartile range (Q1-Q3))	1.298 (1.1 to 1.5)	1.352 (1.2 to 1.7)		

Statistical analyses

No statistical analyses for this end point

Primary: The decline in HIV-1 RNA level (log10 copies/ml) wk1 to wk 2

End point title	The decline in HIV-1 RNA level (log10 copies/ml) wk1 to wk 2 ^[2]
End point description: The decline in HIV-1 RNA level (log10 copies/ml) wk1 to wk 2	
End point type	Primary
End point timeframe: Week 1 to week 2	

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: descriptive statistics only

End point values	Low Copy	High		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	18		
Units: copies/ml				
median (inter-quartile range (Q1-Q3))	0.345 (0.2 to 0.4)	0.393 (0.2 to 0.7)		

Statistical analyses

No statistical analyses for this end point

Primary: The decline in HIV-1 RNA level (log10 copies/ml) wk2 to wk 3

End point title	The decline in HIV-1 RNA level (log10 copies/ml) wk2 to wk 3 ^[3]
-----------------	---

End point description:

The decline in HIV-1 RNA level (log10 copies/ml) wk3 to wk3

End point type	Primary
----------------	---------

End point timeframe:

week 2 to week 3

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: descriptive statistics only

End point values	Low Copy	High		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	18		
Units: copies/ml				
median (inter-quartile range (Q1-Q3))	0.172 (0.1 to 0.4)	0.171 (0.1 to 0.3)		

Statistical analyses

No statistical analyses for this end point

Primary: The decline in HIV-1 RNA level (log10 copies/ml) wk3 to wk4

End point title	The decline in HIV-1 RNA level (log10 copies/ml) wk3 to wk4 ^[4]
-----------------	--

End point description:

The decline in HIV-1 RNA level (log10 copies/ml) wk3 to wk4

End point type	Primary
----------------	---------

End point timeframe:

wk 3 to wk 4

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: descriptive statistics only

End point values	Low Copy	High		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	18		
Units: copies/ml				
median (inter-quartile range (Q1-Q3))	0.03 (-0.1 to 0.2)	0.188 (0 to 0.2)		

Statistical analyses

No statistical analyses for this end point

Primary: The decline in HIV-1 RNA level (log10 copies/ml) wk4 to wk6

End point title	The decline in HIV-1 RNA level (log10 copies/ml) wk4 to wk6 ^[5]
-----------------	--

End point description:

The decline in HIV-1 RNA level (log10 copies/ml) wk4 to wk6

End point type	Primary
----------------	---------

End point timeframe:

wk4-wk6

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: descriptive statistics only

End point values	Low Copy	High		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	18		
Units: copies/ml				
median (inter-quartile range (Q1-Q3))	0.269 (0 to 0.5)	0.241 (0.1 to 0.4)		

Statistical analyses

No statistical analyses for this end point

Primary: The decline in HIV-1 RNA level (log10 copies/ml) wk6 to wk8

End point title	The decline in HIV-1 RNA level (log10 copies/ml) wk6 to wk8 ^[6]
-----------------	--

End point description:

The decline in HIV-1 RNA level (log10 copies/ml) wk6 to wk8

End point type	Primary
----------------	---------

End point timeframe:

wk6-wk8

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: descriptive statistics only

End point values	Low Copy	High		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	18		
Units: copies/ml				
median (inter-quartile range (Q1-Q3))	0.05 (-0.1 to 0.1)	0.286 (0.2 to 0.4)		

Statistical analyses

No statistical analyses for this end point

Primary: The decline in HIV-1 RNA level (log10 copies/ml) wk8 to wk10

End point title	The decline in HIV-1 RNA level (log10 copies/ml) wk8 to
-----------------	---

End point description:

The decline in HIV-1 RNA level (log10 copies/ml) wk8 to wk10

End point type	Primary
----------------	---------

End point timeframe:

wk8-wk10

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: descriptive statistics only

End point values	Low Copy	High		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	18		
Units: copies/ml				
median (inter-quartile range (Q1-Q3))	0.253 (0.1 to 0.4)	0.178 (0 to 0.4)		

Statistical analyses

No statistical analyses for this end point

Primary: The decline in HIV-1 RNA level (log10 copies/ml) wk10 to wk 12

End point title	The decline in HIV-1 RNA level (log10 copies/ml) wk10 to wk 12 ^[8]
-----------------	---

End point description:

The decline in HIV-1 RNA level (log10 copies/ml) wk10 to wk 12

End point type	Primary
----------------	---------

End point timeframe:

wk10 to wk 12

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: descriptive statistics only

End point values	Low Copy	High		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	18		
Units: copies/ml				
median (inter-quartile range (Q1-Q3))	0.159 (0 to 0.3)	0.175 (0 to 0.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: PK parameter AUC at steady-state on day 28

End point title	PK parameter AUC at steady-state on day 28
End point description:	
End point type	Secondary
End point timeframe:	
Day 28	

End point values	Combined Analysis			
Subject group type	Subject analysis set			
Number of subjects analysed	36			
Units: ng/ml				
geometric mean (confidence interval 95%)				
rilpivirine	2966 (2704 to 3280)			
ritonavir	5222 (4567 to 7722)			
darunavir	92504 (82266 to 131107)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK parameter Cmax at steady-state on day 28

End point title	PK parameter Cmax at steady-state on day 28
End point description:	
The PK parameter Cmax for darunavir, rilpivirine and ritonavir at steady-state on day 28	
End point type	Secondary
End point timeframe:	
Day 29	

End point values	Combined Analysis			
Subject group type	Subject analysis set			
Number of subjects analysed	36			
Units: ng/ml				
geometric mean (confidence interval 95%)				
rilpivirine	183 (165 to 239)			
ritonavir	592 (517 to 1036)			
darunavir	9381 (8392 to 12976)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From subject consent until subject's last visit. Also any untoward event that may occur subsequent to the reporting period that the PI assessed as possibly, probably or definitely related to the study drug medication was also be reported as an AE.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.0
--------------------	------

Reporting groups

Reporting group title	Full Analysis Set
-----------------------	-------------------

Reporting group description: -

Serious adverse events	Full Analysis Set		
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 36 (8.33%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Gastrointestinal disorders			
Rectal Trauma			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Prostatitis			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Full Analysis Set		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	36 / 36 (100.00%)		
General disorders and administration site conditions			
Coryza			
subjects affected / exposed	12 / 36 (33.33%)		
occurrences (all)	14		
Fatigue			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	3		
Fever			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	3		
Flu			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Flu symptoms			
subjects affected / exposed	10 / 36 (27.78%)		
occurrences (all)	12		
Flu Vaccine			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Penicillin reaction			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Post Vaccine reaction			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Immune system disorders			
Cough			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	3		
Hayfever			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Sore Throat			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Throat infection</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 36 (16.67%)</p> <p>8</p> <p>1 / 36 (2.78%)</p> <p>1</p>		
<p>Reproductive system and breast disorders</p> <p>Pharyngeal erythema</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Prostatitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 36 (2.78%)</p> <p>1</p> <p>1 / 36 (2.78%)</p> <p>1</p>		
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Bronchitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Catarrh</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Chest infection</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Nose bleed</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Viral upper respiratory tract infection</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 36 (2.78%)</p> <p>1</p> <p>1 / 36 (2.78%)</p> <p>1</p> <p>2 / 36 (5.56%)</p> <p>3</p> <p>1 / 36 (2.78%)</p> <p>1</p> <p>1 / 36 (2.78%)</p> <p>1</p>		
<p>Psychiatric disorders</p> <p>Altered sleep pattern</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Anxiety</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Depression</p>	<p>1 / 36 (2.78%)</p> <p>1</p> <p>5 / 36 (13.89%)</p> <p>5</p>		

subjects affected / exposed occurrences (all)	2 / 36 (5.56%) 2		
Insomnia subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Libido subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Low mood subjects affected / exposed occurrences (all)	2 / 36 (5.56%) 2		
Investigations STI Contact subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Weight lost subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Nervous system disorders Collapsed at work subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Headache subjects affected / exposed occurrences (all)	12 / 36 (33.33%) 15		
Light headedness subjects affected / exposed occurrences (all)	2 / 36 (5.56%) 2		
Migraine subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Occasional headaches subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Transient loss of vision			

subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Ear and labyrinth disorders			
Dizziness			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Ear infection			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Eye disorders			
Conjunctivitis			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Upper abdominal discomfort			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Gastrointestinal disorders			
72HR bug			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Abdominal pain			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Abnormal cramps			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Diarrhoea			
subjects affected / exposed	19 / 36 (52.78%)		
occurrences (all)	24		
Dyspepsia			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Epigastric pain			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Flatulence			

subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Food poisoning			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Gastroenteritis			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Hemorroida			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
intermittent bloating feeling			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Intermittent loose stools			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Loose stool			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	3		
Nausea			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	4		
Pain on left side of stomach			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Pancreatic exocrine insuffici			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Rectal pain			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Reflux oesophagitis			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Stomach bacteria AG pos			

subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Tooth extraction			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	3		
Tooth infection			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Upset stomach			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	6 / 36 (16.67%)		
occurrences (all)	6		
Skin and subcutaneous tissue disorders			
Cellulitis			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Eczema			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Folliculitis (Limb + back)			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Heat rash			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Hordeolum (stye)			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Lipoma			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Lump left knee			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		

Mouth ulcers			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Night sweats			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Oral HSV			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Rash			
subjects affected / exposed	7 / 36 (19.44%)		
occurrences (all)	9		
SPOTS			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Spots on face			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Sun burn			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Periurethral abscess			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Urinary frequency			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
UTI			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	7		
Musculoskeletal and connective tissue disorders			

Ache in muscles subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Back pain subjects affected / exposed occurrences (all)	2 / 36 (5.56%) 2		
Left groin pain subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Muscle strain on the sack subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Pain in elbow subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Placuta fasciitis subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Sciatica subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Strained muscle subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Tennis elbow subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Infections and infestations			
Bacterial infection on face subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Ball pain subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Chlamydia			

subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Clamidia gonorrhoea			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Contact syphilis			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Contact with STI (gonorrhoea)			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Epididymitis			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Fungal infection			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	3		
Gonorrhoea			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	3		
Gum infection			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
HSV (Perioral)			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
HSV flare up			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Impetigo			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Lower respiratory tract infection			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
rectal LGV			

subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Redness in throat			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	2		
respiratory tract infection			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Sinusitis			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Syphilis			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Tinea pedis			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Tonsillitis			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Hunger constantly			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Loss of Appetite			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	2		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
07 February 2014	Inclusion of an interim analysis of the viral load, demographics, AEs and ECG data once the majority of patients had attended their week 4 visits.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Interpretation of this study should take into account its single-arm design and the small number of patients studied, and a larger randomized trial is warranted to draw definite conclusion.

Notes: